MBL was incorporated as a public limited company under the Companies Act, 1956, on December 22, 1993. The certificate of commencement of business was obtained on January 31, 1994. The company has jointly been promoted by Mr.V.Kumar, Mr.Bal Kishan Gupta, Mr.Lakhvinder Singh Arora and Mr.Ranjit Singh. MBL is engaged in marketing of various drugs in the domestic and export markets. Company is procuring drugs from various reputed manufactures viz. Hoechst, Cadila, Hindustan Ciba, Purepharma, Oboi Labs etc. and exporting to countries like Germany, Russia, Holland, CIS (Confederation of Independent States) etc. part from domestic ethical and institutional sales. MBL has obtained permission for production of tablets, capsules and liquid orals under loan licence basis from Delhi Drug Control Authority and Madhya Pardesh Drug Control Authority on Welbeck Pharmaceutical Private Limited, New Delhi and Pure Pharma Private Limited, Indore respectively. 2010 -The Company has recommended a final dividend of Rs. 0.75 per equity share (being 7.5% on the face value of Rs. 10 per share) -The Company appointed Mr. B.K.Gupta as Managing Director. 2011 -The Company gets ANVISA.Brazil approval for Non Beta Lactum solid Tablets and Coated tablets manufactured at its Plant situated at SP 1192,A & B, Phase 4, Bhiwadi - 301019, Rajasthan. 2013 -Ms. Harshita Sharma has been appointed as Additional Director of the company. 2016 -Shivalik Rasayan Ltd take controlling stake of Medicamen Biotech Ltd. 2019 -FABD(Philippines), CECMED(Cuba)-Bhiwadi FDF Plant. 2020 -Global API Facility started Dahej API Plant. 2021 -Operations started Haridwar formulation Unit II(FDF). |
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article